Acute kidney injury risk associated with piperacillin/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function.

@article{Jeon2017AcuteKI,
  title={Acute kidney injury risk associated with piperacillin/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function.},
  author={Nakyung Jeon and Ben Staley and Kenneth P. Klinker and Juan Hincapie Castillo and Almut G Winterstein},
  journal={International journal of antimicrobial agents},
  year={2017},
  volume={50 1},
  pages={63-67}
}
Recent studies have found an association between piperacillin/tazobactam when added to vancomycin and acute kidney injury (AKI) risk. However, studies were limited by the small sample size and residual confounding. The aim of this study was to compare the risk of AKI with vancomycin plus piperacillin/tazobactam (VPT) versus vancomycin plus cefepime (VC) and to examine whether pre-existing renal impairment mediates the risk. This was a retrospective cohort study using electronic health records… CONTINUE READING